News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaxil BioTherapeutics Utilizes Its Vaxhit Technology To Develop Superior Anti-MUC1 Antibodies


1/21/2014 9:25:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Ness Ziona, 21th January 2014. Vaxil Bio (TASE: VAXL), which is developing therapeutic vaccines to treat cancer and infectious diseases, reports today that it has now demonstrated a major new major application for its VaxHit technology. Using VaxHit, Vaxil can isolate signal peptide (SP) epitopes that can be used as antigens for generating more specific antibodies against known and novel targets including the MUC1 tumor marker. These are the first isolated, tumor specific, anti-SP antibodies and their development is based on the unpredicted finding of tumor- associated, cell surface existence of SP epitopes. Other anti-MUC1 antibodies in clinical development are directed against epitopes in MUC1’s extracellular domain which appears on tumor cells but also on patient’s blood thereby having reduced specificity and therapeutic potential. On the contrary, Vaxil’s mAb2.1 and SPmAb-6 anti-MUC1 SP antibodies are targeting only MUC1-expressing tumor cells.

An article, (link attached), discussing Vaxil's discovery and development of the anti-MUC1 signal peptide antibodies including their potential therapeutic role, was recently published in January 2014 in the Scientific Journal, PLos one.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085400 An abstract summarizing these findings will also be presented later on this year at the American association for cancer research (AACR) conference.

Dr. Lior Carmon Vaxil's CEO: "This new finding positions Vaxil’s products in the huge established market for therapeutic antibodies, with a great unmet medical need, at least in the case of current anti-MUC1 antibodies. Furthermore, the observations reported in the PLos-One article,

demonstrated that SPmAb2.1 and SPmAb-6 can also be used as a companion diagnostic to improve patient selection for clinical trials using ImMucin and therefore potential success”.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES